INGHIRAMI, Giorgio
 Distribuzione geografica
Continente #
NA - Nord America 6.199
EU - Europa 5.383
AS - Asia 2.462
AF - Africa 69
OC - Oceania 29
SA - Sud America 22
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.168
Nazione #
US - Stati Uniti d'America 6.091
CN - Cina 1.536
DE - Germania 823
IT - Italia 784
IE - Irlanda 691
SE - Svezia 597
UA - Ucraina 558
FR - Francia 519
KR - Corea 460
FI - Finlandia 424
AT - Austria 252
GB - Regno Unito 181
DK - Danimarca 176
PL - Polonia 161
VN - Vietnam 107
CA - Canada 103
JP - Giappone 95
IN - India 73
SG - Singapore 64
SN - Senegal 58
BE - Belgio 43
ES - Italia 28
HK - Hong Kong 27
NL - Olanda 27
AU - Australia 26
GR - Grecia 22
RU - Federazione Russa 20
TW - Taiwan 20
CH - Svizzera 16
IR - Iran 15
BY - Bielorussia 13
BR - Brasile 12
CZ - Repubblica Ceca 12
RO - Romania 10
QA - Qatar 9
TR - Turchia 9
PH - Filippine 7
PK - Pakistan 7
PT - Portogallo 7
SA - Arabia Saudita 7
CL - Cile 5
EG - Egitto 5
MX - Messico 5
NO - Norvegia 5
RS - Serbia 5
TH - Thailandia 5
UZ - Uzbekistan 5
EU - Europa 4
MO - Macao, regione amministrativa speciale della Cina 4
HU - Ungheria 3
MU - Mauritius 3
MY - Malesia 3
NZ - Nuova Zelanda 3
AR - Argentina 2
IQ - Iraq 2
LU - Lussemburgo 2
NG - Nigeria 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
ID - Indonesia 1
IL - Israele 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
OM - Oman 1
PE - Perù 1
ZA - Sudafrica 1
Totale 14.168
Città #
Beijing 1.003
Chandler 813
Dublin 691
Ann Arbor 414
Villeurbanne 395
Jacksonville 354
Houston 308
Ashburn 305
Princeton 299
Torino 254
Medford 251
Fairfield 243
Vienna 212
Wilmington 193
Dearborn 179
Nyköping 167
Warsaw 158
Woodbridge 117
Redwood City 110
Boston 89
Seattle 80
Cambridge 79
San Mateo 77
Fremont 72
Dong Ket 71
Pisa 70
Milan 69
Boardman 64
Shanghai 60
Guangzhou 48
Toronto 46
Centro 45
Verona 45
Nanjing 42
New York 38
Brussels 35
Singapore 32
Falls Church 31
Norwalk 30
Pune 28
Turin 26
Hefei 25
Chengdu 23
Lachine 23
Tokyo 23
Mountain View 20
Philadelphia 19
Bologna 18
Hangzhou 18
Kunming 18
Düsseldorf 17
Jinan 16
Zhengzhou 16
Ottawa 15
Fuzhou 14
San Diego 14
Washington 14
Los Angeles 13
Nürnberg 13
Taipei 13
Wuhan 13
Phoenix 11
Rome 11
Shenyang 11
Tianjin 11
Detroit 10
Nanchang 10
Xian 10
Columbus 9
Doha 9
Grafing 9
Redmond 9
Wenzhou 9
Changsha 8
Cleveland 8
Des Moines 8
Munich 8
Barcelona 7
Central District 7
Chicago 7
Rochester 7
Changchun 6
Fountain Valley 6
Kish 6
Leiden 6
Thening 6
Austin 5
Buffalo 5
Durham 5
Genova 5
Hebei 5
Hong Kong 5
Kharkiv 5
Monmouth Junction 5
Nagoya 5
New Haven 5
Paris 5
San Jose 5
Silver Spring 5
Tappahannock 5
Totale 8.267
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 669
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. 489
Core binding factor acute myeloid leukaemia and c-KIT mutations 374
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. 337
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. 322
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. 246
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase 240
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation 223
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 222
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors 209
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling 197
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. 173
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK positive anaplastic large cell lymphoma. 171
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 171
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 168
The influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) Biobank 158
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 154
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials 145
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas 144
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 130
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 126
PDX-MI: Minimal information for patient-derived tumor xenograft models 125
The genetics of nodal marginal zone lymphoma 122
Core binding factor acute myeloid leukemia and c-kit mutations 113
Anaplastic lymphoma kinase in human cancer 112
The heterogeneous landscape of ALK negative ALCL 108
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL 108
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 106
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 106
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 105
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas 104
Analysis of the activating Kras mutations in advanced colorectal tumors: a three-year diagnostic experience 95
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 94
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 94
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 89
CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation 89
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma 86
Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination 85
Genomic and functional approaches as powerful tools to stratify human T-cell lymphoproliferative disorders and to identify relevant tumorigenic culprits 84
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination 83
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death 82
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas 82
MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma 80
Anaplastic large-cell lymphoma 79
Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma 78
Molecular anatomy of peripheral T cell lymphomas 76
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 76
Unveiling the pathogenetic role of Stat3 in human lymphoma 73
The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells 73
A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation 72
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells 72
Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation 72
Association of low P27 with loss of hormone receptors in small (T1a/b) breast cancers 72
Dendritic cells transfected with DNA encoding ErbB2 rat/human chimeric plasmids are able to activate in vitro a specific T cell response in ErbB2+ cancer patients 72
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. 72
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. 71
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. 70
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes 70
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA 69
Anaplastic lymphoma Kinase: molecular mechanisms of lymphoid transformation 69
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration 68
Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. 67
Identification of molecular classifiers and key signalling networks in T-cell lymphoproliferative disorders through gene expression profiling meta-analyses 67
Anti-Hu-associated peripheral nerve and muscle microvasculitis. 66
Development of a consensus IgH quantitative assay for the detection of minimal residual disease in Chronic Lymphocytic Leukemia using 3’-minor groove binder probes. 66
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 66
Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. 65
Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity 65
Anaplastic lymphoma kinase: an oncogene for tumor vaccination 65
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase 64
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 64
Induction of germinal centers by MMTV encoded superantigen on B cells. 63
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target 63
Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred? 63
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. 63
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression 62
Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells 61
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? 61
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms 61
The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. 60
CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib 59
ALK protein tyrosine kinase, cells and methods embodying and using same 59
Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells 58
Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas 58
The anaplastic lymphoma kinase in the pathogenesis of cancer 57
N- and K-ras oncogenes in plasma cell dyscrasias. 56
The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. 55
Mutational activation of N-and K-RAS oncogenes in plasma cell dyscrasia. 54
Network-based inference of tumorogenic culprits in human T-cell lymphoproliferative disorders 54
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. 54
Transposable elements: The enemies within 54
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. 53
Gene Expression Profiling Uncovers Molecular Classifiers for theRecognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms 53
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. 52
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas 51
Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human Anaplastic Large Cell Lymphoma cells 49
Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. 49
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. 49
Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. 48
Identification and validation of the anaplastic large cell lymphoma signature 48
Totale 10.806
Categoria #
all - tutte 38.442
article - articoli 0
book - libri 0
conference - conferenze 4.266
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.708


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019335 0 0 0 0 0 0 0 0 0 0 239 96
2019/20202.073 57 74 137 209 166 336 295 146 194 188 165 106
2020/20211.641 183 84 132 100 176 66 183 55 201 167 110 184
2021/20222.179 92 91 100 194 87 154 182 110 71 202 377 519
2022/20232.658 401 208 44 252 221 713 214 130 241 69 88 77
2023/2024997 154 203 61 39 84 200 40 72 15 57 72 0
Totale 14.779